폐 이식 후 신부전 발생 환자에서 유지 면역억제제로서 basiliximab의 사용 평가
Medication Utilization Analysis of Basiliximab as a Maintenance Immunosuppressant in Renal Failure Patients Undergoing Lung Transplantation
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Basiliximab is used as an alternative to tacrolimus in patients with decreased renal function. However, studies on basiliximab as a maintenance immunosuppressant, particularly in patients with lung transplantation, are limited. Therefore, here, we investigated the efficacy and safety of basiliximab in patients with lung transplantation. Methods: Adult patients with acute kidney injury (AKI) who received lung transplantation at a single general hospital between July 1, 2014 and June 30, 2018, were selected and classified in tacrolimus and basiliximab groups. Both groups received a triple-drug regimen (tacrolimus, mycophenolate mofetil, and steroids). However, tacrolimus was discontinued in the basiliximab group when AKI occurred, and two or more repeat basiliximab doses were administered within 3 months after transplantation. The electronic medical records were analyzed retrospectively. Results: Of the 85 patients who met the selection criteria, 61 and 24 were assigned to the tacrolimus and basiliximab groups, respectively. Significant improvement in renal function was observed in the basiliximab group (p <0.001). However, there were no differences in acute and chronic rejection rates in both the groups. No difference was observed in the incidence rate of complications between the groups, except for chronic kidney disease, which showed higher incidence in the basiliximab group (25.0% vs. 4.9%; p =0.013). Conclusions: We suggest the use of basiliximab as an immunosuppressant alternative to tacrolimus in patients with acute renal failure after lung transplantation. Basiliximab demonstrated effectiveness as an immunosuppressant and improved renal function. Therefore, basiliximab can be used in patients with decreased renal function.
Abstract
Background: Basiliximab is used as an alternative to tacrolimus in patients with decreased renal function. However, studies on basiliximab as a maintenance immunosuppressant, particularly in patients with lung transplantation, are limited. Therefore, here, we investigated the efficacy and safety of basiliximab in patients with lung transplantation. Methods: Adult patients with acute kidney injury (AKI) who received lung transplantation at a single general hospital between July 1, 2014 and June 30, 2018, were selected and classified in tacrolimus and basiliximab groups. Both groups received a triple-drug regimen (tacrolimus, mycophenolate mofetil, and steroids). However, tacrolimus was discontinued in the basiliximab group when AKI occurred, and two or more repeat basiliximab doses were administered within 3 months after transplantation. The electronic medical records were analyzed retrospectively. Results: Of the 85 patients who met the selection criteria, 61 and 24 were assigned to the tacrolimus and basiliximab groups, respectively. Significant improvement in renal function was observed in the basiliximab group (p <0.001). However, there were no differences in acute and chronic rejection rates in both the groups. No difference was observed in the incidence rate of complications between the groups, except for chronic kidney disease, which showed higher incidence in the basiliximab group (25.0% vs. 4.9%; p =0.013). Conclusions: We suggest the use of basiliximab as an immunosuppressant alternative to tacrolimus in patients with acute renal failure after lung transplantation. Basiliximab demonstrated effectiveness as an immunosuppressant and improved renal function. Therefore, basiliximab can be used in patients with decreased renal function.
참고문헌 (36)
- Scheffert JL, "Immunosuppression in lung transplantation", J Thorac Dis, 6(8), pp.1039~ (2014)
- 백효채, "폐 이식 수술의 10년 치험", Journal of Chest Surgery, 39(11), pp.822~827 (2006), 대한심장혈관흉부외과학회
- "International Thoracic Organ Transplant (TTX) Registry Data Slides"[URL]
- Roden AC, "Diagnosis of acute cellular rejection and antibody-mediated rejection on lung transplant biopsies : a perspective from members of the pulmonary pathology society", Arch Pathol Lab Med, 141(3), pp.437~444 (2017)
- Chambers DC, "The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation : thirty-fifth adult lung and heartlung transplant report-2018; focus theme : multiorgan transplantation", J Heart Lung Transplant, 37(10), pp.1169~1183 (2018)
- Ivulich S, "Clinical challenges of tacrolimus for maintenance immunosuppression post-lung transplantation", Transplant Proc, 49(9), pp.2153~2160 (2017)
- Knoop C, "Immunosuppressive therapy after human lung transplantation", Eur Respir J, 23(1), pp.159~171 (2004)
- McDermott JK, "Individualizing immunosuppression in lung transplantation", Glob Cardiol Sci Pract, 2018(1), pp.5~ (2018)
- Högerle BA, "Challenging immunosuppression treatment in lung transplant recipients with kidney failure", Transpl Immunol, 35, pp.18~22 (2016)
- TruneČka P, "Renal function in de novo liver transplant recipients receiving different prolongedrelease tacrolimus regimens-The DIAMOND study", Am J Transplant, 15(7), pp.1843~1854 (2015)
- Sikma M, "Pharmacokinetics and toxicity of tacrolimus early after heart and lung transplantation", Am J Transplant, 15(9), pp.2301~2313 (2015)
- Anselm A, "Prolonged basiliximab use as an alternative to calcineurin inhibition to allow renal recovery late after heart transplantation", J Heart Lung Transplant, 27(9), pp.1043~1045 (2008)
- Puttarajappa CM, "Renal complications following lung transplantation and heart transplantation", Crit Care Clin, 35(1), pp.61~73 (2019)
- Ziolkowski J, "Renal function after liver transplantation : calcineurin inhibitor nephrotoxicity", Transplant Proc, 35(6), pp.2307~2309 (2003)
- Cantarovich M, "Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor"holiday"in solid organ transplant patients with acute renal dysfunction1", Transplantation, 73(7), pp.1169~1172 (2002)
- Chapman TM, "Basiliximab : a review of its use as induction therapy in renal transplantation", Drugs, 63(24), pp.2803~2835 (2003)
- Adegunsoye A, "Comprehensive care of the lung transplant patient", Chest, 152(1), pp.150~164 (2017)
- Park JE, "Prevalence of pre-transplant anti-HLA antibodies and their impact on outcomes in lung transplant recipients", BMC Pulm Med, 18(1), pp.45~ (2018)
- Goldstein SL, "Medication-induced acute kidney injury", Curr Opin Crit Care, 22(6), pp.542~545 (2016)
- Moore PK, "Management of Acute Kidney Injury : Core Curriculum 2018", Am J Kidney Dis, 72(1), pp.136~148 (2018)
- "Duration of acute kidney injury"[URL]
- Khwaja A, "KDIGO clinical practice guidelines for acute kidney injury", Nephron Clin Pract, 120(4), pp.c179~84 (2012)
- Verna EC, "Basiliximab induction and delayed calcineurin inhibitor initiation in liver transplant recipients with renal insufficiency", Transplantation, 91(11), pp.1254~1260 (2011)
- "lung transplantation acute rejection"[URL]
- Kim DH, "Analysis of complications of lung and heart-lung transplantations", J Korean Soc Transplant, 17(1), pp.83~87 (2003)
- "Chronic lung transplant rejection: Bronchiolitis obliterans"[URL]
- 함석진, "결핵성 경부 림프절염의 임상 양상과 치료", Journal of Chest Surgery, 43(6), pp.734~738 (2010), 대한심장혈관흉부외과학회
- "Clinical guidelines for transplant medications"[URL]
- "Reimbursement Principles of Healthcare Notification 2020-17"[URL]
- Groetzner J, "Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation", Transplantation, 81(3), pp.355~360 (2006)
- Pham PT, "Acute kidney injury after liver, heart, and lung transplants: dialysis modality, predictors of renal function recovery, and impact on survival", Adv Chronic Kidney Dis, 16(4), pp.256~267 (2009)
- Kim SK, "Is decreased lung function associated with chronic kidney disease? A retrospective cohort study in Korea", BMJ Open, 8(4), pp.e018928~ (2018)
- Randhawa PS, "Tacrolimus(FK506)-associated renal pathology", Adv Anat Pathol, 4(4), pp.265~276 (1997)
- Solé A, "Valencia Lung Transplant Group. Aspergillus infections in lung transplant recipients: risk factors and outcome", Clin Microbiol Infect, 11(5), pp.359~365 (2005)
- Ojo AO, "Chronic renal failure after transplantation of a nonrenal organ", N Engl J Med, 349(10), pp.931~940 (2003)
- Speich R, "Epidemiology and management of infections after lung transplantation", Clin Infect Dis, 33(Suppl 1), pp.S58~S65 (2001)